OSE Immunotherapeutics SA (EPA:OSE)
France · Delayed Price · Currency is EUR 3.176
-0.030 (-0.94%)
Aug 3, 2026, 5:22 PM CET
OSE Immunotherapeutics Ratios and Metrics
Market cap in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 75 | 115 | 157 | 84 | 124 | 187 | |
Market Cap Growth | -49.27% | -26.44% | 87.50% | -32.30% | -33.74% | 66.63% |
Enterprise Value | 89.05 | 119.18 | 137.33 | 100.03 | 142.84 | 180.33 |
Last Close Price | 3.18 | 5.15 | 7.17 | 4.28 | 6.68 | 10.28 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 4.91 | - | - | - |
Forward PE | - | 11.12 | 2.83 | 93.66 | 93.66 | 93.66 |
PS Ratio | 28.02 | 44.09 | 2.25 | 37.60 | 6.76 | 7.09 |
PB Ratio | 2.72 | 4.16 | 2.46 | 3.64 | 3.79 | 3.90 |
P/TBV Ratio | - | - | 7.90 | - | - | - |
P/FCF Ratio | - | - | 3.25 | - | - | - |
P/OCF Ratio | - | - | 3.24 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 33.09 | 45.51 | 1.97 | 44.92 | 7.80 | 6.86 |
EV/EBITDA Ratio | - | - | 4.10 | - | - | - |
EV/EBIT Ratio | - | - | 4.55 | - | - | - |
EV/FCF Ratio | - | - | 2.84 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.25 | 1.25 | 0.71 | 1.96 | 1.34 | 0.76 |
Debt / EBITDA Ratio | - | - | 1.38 | - | - | - |
Debt / FCF Ratio | - | - | 0.95 | - | - | - |
Net Debt / Equity Ratio | 0.13 | 0.13 | -0.31 | 0.71 | 0.59 | -0.13 |
Net Debt / EBITDA Ratio | -0.33 | -0.11 | -0.59 | -0.84 | -1.28 | 0.46 |
Net Debt / FCF Ratio | -0.11 | -0.11 | -0.41 | -0.82 | -1.03 | 0.61 |
Asset Turnover | 0.03 | 0.03 | 0.68 | 0.03 | 0.19 | 0.26 |
Quick Ratio | 1.28 | 1.28 | 3.46 | 1.62 | 1.60 | 2.64 |
Current Ratio | 1.28 | 1.28 | 3.46 | 1.62 | 2.29 | 2.64 |
Return on Equity (ROE) | -82.32% | -82.32% | 86.29% | -82.70% | -44.10% | -30.85% |
Return on Assets (ROA) | -15.66% | -37.31% | 27.54% | -26.20% | -18.80% | -16.37% |
Return on Invested Capital (ROIC) | -50.47% | -100.08% | 68.01% | -49.98% | -38.98% | -38.88% |
Return on Capital Employed (ROCE) | -19.99% | -47.63% | 36.14% | -33.13% | -23.01% | -19.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | - | - | 20.36% | - | - | - |
FCF Yield | - | - | 30.81% | - | - | - |
Buyback Yield / Dilution | -5.12% | -2.20% | -11.48% | -5.58% | -2.05% | -16.71% |
Total Shareholder Return | -5.12% | -2.20% | -11.48% | -5.58% | -2.05% | -16.71% |